Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.91 USD | +0.23% | +3.47% | +7.98% |
Financials (USD)
Sales 2024 * | 954M | Sales 2025 * | 1.1B | Capitalization | 5.07B |
---|---|---|---|---|---|
Net income 2024 * | 370M | Net income 2025 * | 484M | EV / Sales 2024 * | 6.26 x |
Net Debt 2024 * | 899M | Net Debt 2025 * | 422M | EV / Sales 2025 * | 4.98 x |
P/E ratio 2024 * |
13.1
x | P/E ratio 2025 * |
9.66
x | Employees | 373 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.88% |
Latest transcript on Halozyme Therapeutics, Inc.
1 day | +0.23% | ||
1 week | +3.47% | ||
Current month | +4.75% | ||
1 month | +0.45% | ||
3 months | +18.50% | ||
6 months | +12.17% | ||
Current year | +7.98% |
Managers | Title | Age | Since |
---|---|---|---|
Helen Torley
CEO | Chief Executive Officer | 61 | 14-01-05 |
Nicole LaBrosse
DFI | Director of Finance/CFO | 41 | 14-12-31 |
Mark Snyder
CMP | Compliance Officer | 57 | 22-01-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Connie Matsui
BRD | Director/Board Member | 70 | 06-07-30 |
Chairman | 59 | 15-08-04 | |
Barbara Duncan
BRD | Director/Board Member | 59 | 23-02-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.48% | 5 M€ | -1.80% | - | |
0.73% | 0 M€ | 0.00% | - | |
0.55% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 39.91 | +0.23% | 902,802 |
24-05-02 | 39.82 | +1.32% | 832,175 |
24-05-01 | 39.3 | +3.15% | 1,031,838 |
24-04-30 | 38.1 | -1.73% | 922,527 |
24-04-29 | 38.77 | +0.52% | 728,580 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.98% | 5.07B | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- HALO Stock